# Phase 1 Study of CM082 in Patients With wAMD

> **NCT02452385** · PHASE1 · SUSPENDED · sponsor: **AnewPharma** · enrollment: 56 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** CM082 tablet

## Key facts

- **NCT ID:** NCT02452385
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2015-03
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 56 (ESTIMATED)
- **Why stopped:** Sponsor requirements
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452385, "Phase 1 Study of CM082 in Patients With wAMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02452385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*